
MilliporeSigma Opens Production Facility in Mollet des Vallès
The company opened a facility in Spain dedicated to the production of meglumine.
On Jan. 17, 2017, MilliporeSigma announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media. The FDA-validated facility in Spain is solely dedicated to the production of meglumine, an amino sugar derived from glucose. As an excipient, meglumine interacts directly with APIs to increase solubility. Therefore, the manufacture of meglumine must meet the same stringent regulatory and quality requirements as APIs, the company said in a statement.
This follows an
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.